<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04854369</url>
  </required_header>
  <id_info>
    <org_study_id>2021-583</org_study_id>
    <nct_id>NCT04854369</nct_id>
  </id_info>
  <brief_title>68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly)</brief_title>
  <acronym>Firefly</acronym>
  <official_title>68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tulane University</source>
  <brief_summary>
    <textblock>
      This is a prospective, Phase 2, single-center, open-label study of 68Ga-PSMA-11 PET scans in&#xD;
      patients with biochemically recurrent prostate cancer or those diagnosed and untreated with&#xD;
      high risk or very high risk localized prostate cancer, or oligometastatic (defined as three&#xD;
      or fewer metastatic lesions on conventional imaging) prostate cancer (using NCCN&#xD;
      classification for localized disease).&#xD;
&#xD;
      Approximately 300 patients are planned for enrollment in this study, divided into two&#xD;
      cohorts. Cohort A will be 225 patients in the recurrent setting. Cohort B will be 75 patients&#xD;
      in the up-front newly diagnosed setting.&#xD;
&#xD;
      After a screening period (6-week window), eligible patients will undergo baseline assessments&#xD;
      as per the Schedule of Study Activities. Patients will receive a single dose of 68Ga-PSMA-11&#xD;
      and undergo a PET/CT or PET/MRI imaging study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Prostatic Neoplasms</condition>
  <condition>Prostatic Neoplasms, Castration-Resistant</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68 Ga-PSMA-11 prepared using a PSMA-11 Sterile Cold Kit</intervention_name>
    <description>The PSMA-11 Sterile Cold Kit is supplied as a kit for preparation of radiolabeled Gallium-68 PSMA-11 Injection, with 3 configurations (A, B or D) to accommodate the specificities of the 68Ge/68Ga generator that is used.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males greater than 18 years of age.&#xD;
&#xD;
          -  Histologically proven adenocarcinoma of the prostate. Diagnosis must be stated in a&#xD;
             pathology report and confirmed by the investigator.&#xD;
&#xD;
          -  Patients must meet the criteria of one of the following cohorts:&#xD;
&#xD;
        Cohort A: (n=225) Biochemical recurrence; defined as any of the following:&#xD;
&#xD;
          -  PSA ≥ 0.2 ng/mL and rising in at least two consecutive tests (at least one week apart)&#xD;
             within 6 months of date of consent for patients treated with radical prostatectomy.&#xD;
&#xD;
          -  PSA &gt;2.0 ng/mL above the nadir and rising post-radiation (external beam or&#xD;
             brachytherapy) +/- hormones, in at least 2 consecutive tests (at least one week apart)&#xD;
             within 6 months of consent&#xD;
&#xD;
          -  In patients with no prior definitive surgery or radiation, PSA ≥ 2 ng/mL greater than&#xD;
             the post therapy nadir after androgen deprivation therapy.&#xD;
&#xD;
        Note: Patients whom have had more than one prior therapy, should be defined recurrent by&#xD;
        their most recent therapy type. For patients who have had any ADT, are mCRPC, shall fall&#xD;
        into that category for allocation and eligibility.&#xD;
&#xD;
        Cohort B: (n=75) No prior treatment defined as one of the following:&#xD;
&#xD;
        o Patient has primary diagnosis of &quot;high risk&quot; or &quot;very high risk&quot; localized prostate&#xD;
        cancer, or regional prostate cancer (TxN1M0) or oligometastatic cancer (TxNXM1) with less&#xD;
        than three metastatic lesions by conventional imaging) and has not received prior&#xD;
        treatment.&#xD;
&#xD;
        Note: high risk/very high risk is denoted by Gleason 8-10, or PSA &gt;20, or clinical stage&#xD;
        T3a/T4 disease (see NCCN guidelines v1.2020).&#xD;
&#xD;
        Patients in this cohort must be considered candidates for initial definitive therapy at the&#xD;
        time of study enrollment.&#xD;
&#xD;
          -  Life expectancy of &gt;6 months&#xD;
&#xD;
          -  Patients should have a Comprehensive Metabolic Panel, PSA, and Testosterone drawn&#xD;
             within 4 weeks of imaging&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Claustrophobia or any other condition that would preclude PET/CT imaging.&#xD;
&#xD;
          -  Patients with known metastatic prostate cancer, with 4 or more lesions on conventional&#xD;
             imaging&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Alton O Sartor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charlotte Manogue</last_name>
    <phone>504-988-3908</phone>
    <email>cmanogue@tulane.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Minqi Huang</last_name>
    <phone>504-988-6126</phone>
    <email>mhuang6@tulane.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tulane Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Charlotte Manogue</last_name>
      <phone>504-988-3908</phone>
      <email>cmanogue@tulane.edu</email>
    </contact>
    <contact_backup>
      <last_name>Minqi Huang</last_name>
      <phone>504-988-6126</phone>
      <email>mhuang6@tulane.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Alton O Sartor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010 Nov 15;116(22):5226-34. doi: 10.1002/cncr.25456. Erratum in: Cancer. 2011 Jun 15;117(12):2825.</citation>
    <PMID>20690197</PMID>
  </reference>
  <reference>
    <citation>Wallis CJD, Saskin R, Choo R, Herschorn S, Kodama RT, Satkunasivam R, Shah PS, Danjoux C, Nam RK. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016 Jul;70(1):21-30. doi: 10.1016/j.eururo.2015.11.010. Epub 2015 Dec 15. Review.</citation>
    <PMID>26700655</PMID>
  </reference>
  <reference>
    <citation>Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol. 2002 Jan;167(1):117-22. Erratum in: J Urol. 2004 Feb;171(2 Pt 1):811.</citation>
    <PMID>11743287</PMID>
  </reference>
  <reference>
    <citation>Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, Klein E, Michalski J, Roach M, Sartor O, Wolf JS Jr, Faraday MM. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013 Aug;190(2):441-9. doi: 10.1016/j.juro.2013.05.032. Epub 2013 May 21.</citation>
    <PMID>23707439</PMID>
  </reference>
  <reference>
    <citation>Moreira DM, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol. 2009 Nov;182(5):2250-5. doi: 10.1016/j.juro.2009.07.022. Epub 2009 Sep 16.</citation>
    <PMID>19758614</PMID>
  </reference>
  <reference>
    <citation>Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007 May 20;25(15):2035-41. Erratum in: J Clin Oncol. 2007 Sep 10;25(26):4153.</citation>
    <PMID>17513807</PMID>
  </reference>
  <reference>
    <citation>Ajib K, Zanaty M, Alnazari M, Rajih E, Hueber PA, Mansour M, Valdivieso R, Negrean C, Karakiewicz PI, Taussky D, Delouya G, El-Hakim A, Zorn KC. Functional and oncological outcomes of salvage external beam radiotherapy following robot-assisted radical prostatectomy in a Canadian cohort. Can Urol Assoc J. 2018 Feb;12(2):45-49. doi: 10.5489/cuaj.4641. Epub 2017 Dec 1.</citation>
    <PMID>29381466</PMID>
  </reference>
  <reference>
    <citation>Freedland SJ, Rumble RB, Finelli A, Chen RC, Slovin S, Stein MN, Mendelson DS, Wackett C, Sandler HM; American Society of Clinical Oncology. Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2014 Dec 1;32(34):3892-8. doi: 10.1200/JCO.2014.58.8525. Epub 2014 Nov 3. Review.</citation>
    <PMID>25366677</PMID>
  </reference>
  <reference>
    <citation>Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Jun 1;5(6):856-863. doi: 10.1001/jamaoncol.2019.0096.</citation>
    <PMID>30920593</PMID>
  </reference>
  <reference>
    <citation>Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30. Erratum in: Lancet Oncol. 2019 Nov;20(11):e613. Erratum in: Lancet Oncol. 2020 Jun;21(6):e304.</citation>
    <PMID>31375469</PMID>
  </reference>
  <reference>
    <citation>Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N. Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016 Dec;70(6):926-937. doi: 10.1016/j.eururo.2016.06.021. Epub 2016 Jun 28. Review.</citation>
    <PMID>27363387</PMID>
  </reference>
  <reference>
    <citation>Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K. (68)Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024. doi: 10.1007/s00259-017-3670-z.</citation>
    <PMID>28283702</PMID>
  </reference>
  <reference>
    <citation>Hope TA, Goodman JZ, Allen IE, Calais J, Fendler WP, Carroll PR. Metaanalysis of (68)Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. J Nucl Med. 2019 Jun;60(6):786-793. doi: 10.2967/jnumed.118.219501. Epub 2018 Dec 7. Review.</citation>
    <PMID>30530831</PMID>
  </reference>
  <reference>
    <citation>Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):486-95. doi: 10.1007/s00259-012-2298-2. Epub 2012 Nov 24. Erratum in: Eur J Nucl Med Mol Imaging. 2013 May;40(5):797-8.</citation>
    <PMID>23179945</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>68 Ga-PSMA-11</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Metastatic prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

